Compare CDLX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | AIMD |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.6M |
| IPO Year | 2018 | 2008 |
| Metric | CDLX | AIMD |
|---|---|---|
| Price | $1.27 | $1.18 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.43 | N/A |
| AVG Volume (30 Days) | 61.1K | ★ 3.9M |
| Earning Date | 11-05-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | $124,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 498.95 |
| 52 Week Low | $0.55 | $0.43 |
| 52 Week High | $6.40 | $3.88 |
| Indicator | CDLX | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 27.28 | 61.97 |
| Support Level | $0.85 | $0.56 |
| Resistance Level | $2.32 | $1.68 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 2.83 | 47.96 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.